We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Vimovo

News List

Aralez completes sale of drug rights to Nuvo Pharmaceuticals for $110m pharmaceutical-technology
January 03, 2019
Canada-based Aralez Pharmaceuticals has completed the divestment of more than 20 medicines under its portfolio to Nuvo Pharmaceuticals for a total consideration of $110m......
Grünenthal buys certain rights to AZ’s Nexium and Vimovo for $922m pharmaphorum
December 18, 2018
AstraZeneca has agreed to sell some of the rights to its drugs Nexium and Vimovo to Grünenthal for an upfront payment of $922 million.
AZ sheds Nexium, Vimovo rights to Gruenenthal pharmatimes
November 05, 2018
AstraZeneca is continuing to shed products outside the scope of its three core therapy areas with the sale of certain rights to Nexium...
AstraZeneca flogs two drug licenses in $922 million deal pharmafile
November 01, 2018
AstraZeneca has signed a deal with Grünenthal worth up to $922 million in which the latter will acquire the regional rights to two of the pharma giant’s drugs.
Agreement with Grünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US) worldpharmanews
October 31, 2018
AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal.